According to Ameco Research, the worldwide market for Gene Amplification Technologies will increase at a CAGR of more than 8% throughout the forecast period, reaching a market size of more than USD 50,630 Million by 2028.
According to the World Cancer Research Fund, the worldwide toll of cancer cases was more than 18 million in 2020. Out of these, more than 9 million cases were in men and more than 8 million in women. Gene amplification is the process of increasing the number of copies of a gene. The number of copies of a gene increases without the number of copies of other genes increasing. A rise in gene products, such as RNA and protein, is also possible. It can occur naturally or be induced purposefully in order to obtain the desired gene product. For e.g. multiple copies of a gene are occasionally created in cancer cells as a result of receiving signals from other cells or the environment. The polymerase chain reaction is used to artificially amplify genes in a lab (PCR). An amplicon is a piece of DNA or a gene that is amplified either naturally or artificially.
Several processes have been proposed to explain gene amplification's emergence. These have mostly been predicated on in vitro systems in which treatment resistance is selected; hence the mechanisms involved in de novo oncogene amplification may differ. However, loss of cell cycle regulation, DNA damage or instability, and a stimulus to continue through the cell cycle may be required for gene amplification to occur.
Request for a sample of this premium research report @ https://www.amecoresearch.com/sample/276603
The increasing adoption of gene amplification in cancer studies fuels the market growth
Gene amplification is a common genetic change in cancer, and several oncogenes have been found in amplified regions in the past. Novel cancer-associated genes may still be discovered in the expanded regions in this regard. Co-amplified genes also contribute to cancer in tandem with known oncogenes in the same amplicons, according to recent comprehensive techniques. Gene amplification is an effective acceleration mechanism to increase carcinogenesis, given that cancer grows through the change of many genes. The discovery of cancer-related genes could lead to the development of new and effective treatment targets.
Human epidermal growth factor receptor 2 (HER2)-amplified breast tumors have chromosomal 17q rearrangements, which result in frequent gene amplifications. The human epidermal growth factor receptor 2 (HER2) gene is amplified on chromosome 17q (Chr17q) in roughly 15% to 20% of breast tumors. Amplification of the HER2 gene is linked to aggressive tumor behavior (more metastatic potential and shorter survival), as well as the patient's response to trastuzumab therapy.
The increasing number of research & development activities in fields such as advanced DNA multiplication, drug discovery, gene and genomic testing, and molecular diagnostic is expected to attain a significant impetus in the coming years. However, lack of awareness and limited funding in emerging economies, and the high cost of these technologies are some of the aspects that are expected to limit the market growth.
Global Gene Amplification Technologies Market Segmentation
The global gene amplification technologies segmentation includes the product, sample type, technology, application, end-use, and geography. The product segment includes instruments, kits & reagents, and services. Among products, kits & reagents accounted for the majority of the share in 2020. Single cells, FFPE, and others are considered in the sample type segment. Others segment was the largest revenue-generating while single-cell were the second-largest revenue-generating segment in 2020.
Based on technology, the segmentation comprises multiple displacement amplification, PCR-based amplification, nucleic acid sequence-based amplification, loop-mediated isothermal amplification, strand displacement amplification, ramification amplification, rolling circle amplification, and others. Among them, PCR-based amplification acquired the largest market share in 2020 due to the extensive use of PCR technology across a variety of end-use applications. Furthermore, the prevalent use of PCR for COVID-19 detection has resulted in significant income for this method.
By application, the market is categorized into whole genome amplification, hybridization, exome sequencing, array CGH, SNP genotyping arrays, and others. Among applications, the hybridization segment gathered a significant amount of share in 2020. The exome sequencing stood for the second position during the same year. Academic & research institutes, pharmaceutical & biotechnology companies, and others are the categorizations of the end-use segment.
Furthermore, North America, Asia-Pacific, Latin America, Europe, and the Middle East & Africa are the regional categorization of the global gene amplification technologies market. In 2020, North America subjugated the major chunk of the market due to primary reasons such as the rising number of cancer patients, increasing emphasis on the fields such as gene and genome testing and drug delivery, and early adoption of technologies. However, the Asia-Pacific region is likely to attain the fastest growth due to improvements in the healthcare infrastructure, rising awareness for gene and genome research, and increasing government spending in the health and pharma sectors.
Major Players
The prominent players offered in the report include Abbott Laboratories, Ambion, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Danaher Corporation, Illumina Inc., QIAGEN N.V., Merck KGaA, Promega Corporation, Silicon Biosystems, Vazyme Biotech Co. Ltd., and Takara Bio, Inc.
To receive personalized service, please share your research needs here@ https://www.amecoresearch.com/enquiry-before-buy/276603
Buy this premium research report - https://www.amecoresearch.com/buy/276603
Contact Us:
Mr. Richard
Ameco Research
USA: +1 347 474 3864
India: +91 8983225533
E-mail: sales@amecoresearch.com